IP Library Granted Patent US 9,464,328
Granted Patent B2
US 9,464,328 · App. 14/454,552 · Granted Oct 11, 2016

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Inventors: Steven Buechler (Granger, IN); Amanda B. Hummon (Granger, IN)
Assignee: UNIVERSITY OF NOTRE DAME
C12Q1/6886G01N33/57419C12Q2600/106C12Q2600/118C12Q2600/158G01N2800/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,328
App. No.
14/454,552
Granted
Oct 11, 2016
Kind
B2
Abstract

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

Claims (31)

1. A panel of probes for indicating a 5-year left-side colon cancer (LCC) relapse probability of LCC in a post-surgery human LCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of NOX4, MMP3, SLC16A6, WNT5A, CYP1B1, IBSP, TFAP2C, MATN3 and ANKRD6.

2. The panel of probes of claim 1 , wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface.

3. The panel of probes of claim 1 , wherein the detectable label is a fluorescent label or a radiolabel.

4. The panel of probes of claim 2 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

5. The panel of probes of claim 2 wherein the solid surface is a silicon wafer.

6. The panel of probes of claim 2 wherein the solid surface is a glass.

7. The panel of probes of claim 6 wherein the solid surface is a glass slide or a glass chip.

8. The panel of probes of claim 2 wherein the probes are fixed to the solid surface by a covalent bond.

9. The panel of probes of claim 1 wherein the probes are fixed to a solid surface in a kit form.

10. The panel of probes of claim 9 , wherein the detectable label of the probes is a fluorescent label or a radiolabel.

11. The panel of probes of claim 9 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

12. The panel of probes of claim 9 wherein the solid surface is a silicon wafer.

13. The panel of probes of claim 9 wherein the solid surface is a glass.

14. The panel of probes of claim 9 wherein the solid surface is a glass slide or a glass chip.

15. The panel of probes of claim 9 wherein the probes are fixed to the solid surface by a covalent bond.

16. A panel of probes for indicating a 5-year LCC relapse probability of LCC in a post-surgery human LCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of NOX4 and MMP3.

17. The panel of probes of claim 16 , wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface.

18. The panel of probes of claim 16 , wherein the detectable label is a fluorescent label or a radiolabel.

19. The panel of probes of claim 17 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

20. The panel of probes of claim 17 wherein the solid surface is a silicon wafer.

21. The panel of probes of claim 17 wherein the solid surface is a glass.

22. The panel of probes of claim 21 wherein the solid surface is a glass slide or a glass chip.

23. The panel of probes of claim 17 wherein the probes are fixed to the solid surface by a covalent bond.

24. A panel of probes for indicating a 5-year left-side colon cancer (LCC) relapse probability of LCC in a post-surgery human LCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of at least five genes selected from the group consisting of NOX4, MMP3, SLC16A6, WNT5A, CYP1B1, IBSP, TFAP2C, MATN3 and ANKRD6.

25. The panel of probes of claim 24 , wherein the detectably labeled single-stranded polynucleotides are immobilized to a solid surface.

26. The panel of probes of claim 24 , wherein the detectable label is a fluorescent label or a radiolabel.

27. The panel of probes of claim 25 , wherein the solid surface is nylon, plastic, silicon, or ceramic.

28. The panel of probes of claim 25 wherein the solid surface is a silicon wafer.

29. The panel of probes of claim 25 wherein the solid surface is a glass.

30. The panel of probes of claim 25 wherein the solid surface is a glass slide or a glass chip.

31. The panel of probes of claim 25 wherein the probes are fixed to the solid surface by a covalent bond.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2014
From: BUECHLER, STEVEN; HUMMON, AMANDA
To: UNIVERSITY OF NOTRE DAME
Reel/Frame 033631/0199 →
Continuity (4)
Division 13332071 · Dec 20, 2011
Provisional Application 61462592 · Feb 4, 2011
Provisional Application 61459864 · Dec 20, 2010
Related Publication 20150073035A1 · Mar 12, 2015